CoChat

Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Open access
Zhao, Kewei, Wang, Chunsheng, Shi, Fang, Huang, Yong, Ma, Li, Li, Minghuan, Song, Yipeng · 2021 · BMC Cancer

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Background: We evaluated the prognostic potential of tumor 18 F-fluorodeoxyglucose (FDG) uptake derived from positron emission tomography (PET) and known inflammatory hematological markers, both individually and in combination, for chemosensitivity and survival in patients with stage IIIB-IV non-small cell lung cancer (NSCLC) receiving first-line chemotherapy. Methods: A total of 149 patients with stage IIIB and IV NSCLC (based on TNM 7th edition) were retrospectively reviewed. Maximum standardized uptake value (SUVmax) were used to quantitatively assess FDG uptake. The lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were selected as hematological markers. Receiver operating characteristic (ROC) curves were constructed for the determination of optimal cut-off values to predict chemotherapeutic response. Results: Patients with SUVmax > 11.6 or LMR ≤3.73 exhibited a significantly lower objective response rate (ORR) to chemotherapy ( p < 0.001 and p < 0.001). Through multivariable logistic regression analysis, both the SUVmax and LMR were identified as independent predictive factors for chemotherapeutic response ( p = 0.001 and p < 0.001). Furthermore, a multivariable Cox proportional hazard model identified a high SUVmax (> 11.6) and low LMR (≤3.73) as independent predictors of poor PFS ( p < 0.001 and p = 0.025) and OS ( p < 0.001 and p = 0.032). A novel score system was constructed based on the SUVmax and LMR (SUV_LMR score), and patients were stratified into three subgroups. The patients with a score of 0 had a significantly higher ORR (88.9%) than did those with a score of 1 (59.6%) and score of 2 (25.0%) ( p < 0.001). Moreover, multivariable Cox analysis further identified the SUV_LMR score as an independent prognostic factor for PFS ( p < 0.001) and OS ( p < 0.001). Conclusions: Pre-treatment SUVmax and LMR were not only predictive factors for chemotherapeutic response but also independent prognostic factors of survival in stage IIIB-IV NSCLC. Moreover, the SUV_LMR score, which is based on primary tumor metabolic activity and the systemic inflammatory response, might provide a promising tool to predict chemosensitivity, recurrence and survival of advanced NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-021-07784-x

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Correlation between SUVmax and hematological markers LMR a, NLR b and PLR c
Fig. 1 Correlation between SUVmax and hematological markers LMR a, NLR b and PLR cCC BY · PubMed Central
Fig. 2 Receiver operating characteristic curves for SUVmax and hematological markers
Fig. 2 Receiver operating characteristic curves for SUVmax and hematological markersCC BY · PubMed Central
Fig. 3 Kaplan–Meier analyses of 149 patients with stage IIIB-IV NSCLC. a Progression-free survival curves according to SUVmax. b Overall survival curves according to SUVmax. c Progression-free survival curves according to LMR. d Overall survival curves according to LMR
Fig. 3 Kaplan–Meier analyses of 149 patients with stage IIIB-IV NSCLC. a Progression-free survival curves according to SUVmax. b Overall survival curves according to SUVmax. c Progression-free survival curves according to LMR. d Overall survival curves according to LMRCC BY · PubMed Central
Fig. 4 Kaplan–Meier analyses for progression-free survival a and overall survival b of IIIB-IV NSCLC patients according to the SUV_LMR score (0,1 and 2)
Fig. 4 Kaplan–Meier analyses for progression-free survival a and overall survival b of IIIB-IV NSCLC patients according to the SUV_LMR score (0,1 and 2)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 21

Metadata

Authors
Zhao, K., Wang, C., Shi, F., Huang, Y., Ma, L., Li, M., & Song, Y.
Affiliations
  • Yuhuangding Hospital (CN)
  • Shandong University (CN)
Corresponding author
Song, Yipeng
Venue
BMC Cancer
Published
2021-01-14
Volume
21
Issue
1
Pages
66-66
ISSN
1471-2407 (ISSN-L)
OpenAlex
W3123041309
Cited by
21
References
39
Citations by year
2026: 5 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
non-small cell lung cancer, FDG-PET, SUVmax, lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic factors, chemotherapy response prediction, first-line chemotherapy, objective response rate, progression-free survival, overall survival, inflammatory markers, stage IIIB/IV NSCLC
MeSH terms
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Lymphocytes, Male, Middle Aged, Monocytes, Prognosis, Retrospective Studies, Survival Rate, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. https://app.cochat.ai/papers/10.1186/s12885-021-07784-x
The paper
Zhao, K., Wang, C., Shi, F., Huang, Y., Ma, L., Li, M., & Song, Y. (2021). Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. BMC Cancer. https://doi.org/10.1186/s12885-021-07784-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.